Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia

Journal of Clinical Psychopharmacology

Volumn 33, Issue 3, 2013, Pages 425-431

  Gao, Keming ^a   Pappadopulos, Elizabeth ^b   Karayal, Onur N ^b   Kolluri, Sheela ^b   Calabrese, Joseph R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b PFIZER INC   (United States)

Author keywords

adverse events; bipolar disorder; number needed to treat to harm; schizophrenia

Indexed keywords

PLACEBO; ZIPRASIDONE;

AKATHISIA; ARTICLE; BIPOLAR DISORDER; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MANIA; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SLEEP STAGES; THIAZOLES; WEIGHT GAIN;

EID: 84877580987     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182917f3f     Document Type: Article

References (23)

1. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherenceproblems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009; 70(suppl 4): 1-46.
2. Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010; 13: 5-14.
3. Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008; 69: 302-309.
4. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008; 28: 203-209.
5. Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 2011; 72(8): 1063-1071.
6. Wang Z, Kemp DE, Chan PK, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol. 2011; 14: 131-142.
7. Geodon [prescribing information] New York, NY: Pfizer Inc; 2006.
8. Sachs G, Lombardo I, Yang R, et al. Lessons from the ziprasidone bipolar depression program. Presented at: 49th Annual Meeting of the New Clinical Drug Evaluation Unit; 2009; Hollywood, F.L.
9. Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011; 72: 1413-1422.
10. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999; 20: 491-505.
11. Keck PE, Reeves KR, Harrigan EP. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol. 2001; 21: 27-35.
12. Keck PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003; 160: 741-748.
13. Keck PE, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl). 1998; 140: 173-184.
14. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005; 25: 301-310.
15. Rappard F, Warrington LE, Lombardo I, et al. Efficacy of ziprasidone in the treatment of schizoaffective disorder: an analysis of 2 fixed-dose, placebo-controlled trials. Presented at: 19th Congress of the European College of Neuropsychopharmacology; September 16, 2006; Paris, Franc.e.
16. Vieta E, Ramey T, Keller D, et al. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol. 2010; 24: 547-558.
17. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006; 59: 990-996.
18. Citrome L, Yang R, Glue P, et al. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr Res. 2009; 111: 39-45.
19. Citrome L, Reist C, Palmer L, et al. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Schizophr Res. 2009; 115: 115-120.
20. Sharif Z. Side effects as influencers of treatment outcome. J Clin Psychiatry. 2008; 69(suppl 3): 38-43.
21. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
22. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009; 4: CD006627.
23. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009; 110: 103-110.